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Robert J. SoifferA 41 year old man presents to you with pancyto-
penia. He is asymptomatic except for mild fatigue.
Liver, pulmonary, and kidney function are normal.
Bone marrow biopsy is normocellular with multiline-
age dysplasia. Myeloblasts represent 15% of the mar-
row cellularity. There are no circulating peripheral
blasts. Chromosome analysis reveals monosomy 7 in
13 of 20 metaphases. The patient’s brother is healthy
and HLA-identical. Based on the patient’s diagnosis
of myelodysplastic syndrome, high international
prognostic scoring system, lack of comorbidities,
and available HLA-identical sibling donor, you rec-
ommend allogeneic hematopoietic cell transplanta-
tion (HCT) [1].
Your fellow asks you, ‘‘Do you think we should
treat the patient first in order to decrease the number
of marrow blasts before transplantation? Will that
lead to lower relapse rates and superior long term sur-
vival? Should we use a hypomethylating agent or do
you think full leukemia induction with cytosine arabi-
noside and anthracycline is best?’’ You pause, stroke
your chin, and prepare to educate your knowledge
hungry fellow. But the best you can do is reply, ‘‘I
don’t know.’’
Although allogeneic HCT has been performed
for myelodysplasia for over 25 years, there remains
no clear consensus on the advisability of cyto-reductive therapy before transplantation. Unfortu-
nately, there are no randomized trials to help guide
practitioners and retrospective studies are generally
subject to selection bias. Nonetheless, Scott et al.
[2] reported in Biology of Blood and Marrow Transplan-
tation in 2005 a series of 125 patients with advanced
myelodysplastic syndrome (MDS) treated in Seattle
with myeloablative transplantation. In that retrospec-
tive series, 33 patients received induction chemother-
apy whereas 92 patients were taken directly to
transplantation. No significant difference in relapse-
free or overall survival was noted in patients who
had received pretransplant chemotherapy compared
with those who were chemotherapy na€ıve. This of
course does not even account for those patients
with advanced MDS who received induction chemo-
therapy and never received a transplantation either
because of morbidity from treatment or lack of re-
sponse to the induction chemotherapy. Nakia et al.
[3] reported a similar experience from Japan, again
in ablative transplantation recipients. The impact of
induction chemotherapy may be different in patients
receiving nonmyeloablative conditioning as the expe-
rience reported by Warlick et al. [4] in Minnesota
suggested a trend for better outcome in nonmyeloa-
blative recipients who had received pretransplant
treatment.
In this issue of the Biology of Blood and Marrow
Transplantation, Saure et al. [5] present a novel strategy
for patients with advanced MDS. They treated 30
patients with fludarabine, amsacrine, and cytosine
arabinoside followed 2 to 3 days later by high dose
melphalan-based conditioning and allogeneic hemato-
poietic stem cell infusion. Thus, induction chemother-
apywas actually combinedwith allogeneicHCT rather
than delivered as a 2-step process. They report an en-
couraging 63% 2-year disease-free survival estimate.
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ing these results. The patients included in this series
were heterogeneous with a third having refractory cy-
topenia withmultilineage dysplasia and refractory ane-
mia with excess blasts-1 and 40% reported as having
‘‘good’’ cytogenetics. None had received prior hypo-
methylating agents which may skew the population.
Relapses were still observed beyond 2 years so durabil-
ity of the 2-year survival outcomes is uncertain. No
data are presented which correlate percentage of mar-
row blasts at transplantation with risk of posttrans-
plantation relapse. Nonrelapse mortality was high
(30%) and correlated with intensity of transplant con-
ditioning, raising questions about applicability of this
strategy to older patients, such as those aged 60 and
higher. It is particularly important to focus on this
older population as they represent an increasing per-
centage of patients for which HCT is performed for
MDS and they generally receive reduced intensity con-
ditioning. Combining induction chemotherapy with
aggressive transplantation conditioning may not be
tolerable for this cohort.
Althoughwe can now add this report by Saure et al.
[5] to the literature we give to our fellows, we still are
not really any closer to determining the best course of
action for our patient presented above. It will take
a large committed multicenter effort to test this
strategy in a prospective randomized trial. Given theincreasing frequency of MDS as a transplant indica-
tion, it is a question we as a community should answer.ACKNOWLEDGMENTS
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